"The FDA approved the medication, called Foundayo, for market on April 1. Unlike most other GLP-1 drugs, the pill can be taken at any time of day without food or water restrictions."
"In a Lilly-funded trial published by The Lancet, patients on 12 to 36 milligrams of orforglipron, the active ingredient in Foundayo, lost an average of 15 to 20 pounds."
"Lilly's pill 'outperformed' Novo's 'on every key endpoint we measured, including A1C and weight loss,' lead trial investigator Dr. Julio Rosenstock said in a release."
Eli Lilly's Foundayo received FDA approval on April 1 for weight loss in adults with obesity or weight-related health conditions. Unlike other GLP-1 medications, Foundayo can be taken at any time without food or water restrictions. It has shown superior results in trials, with patients losing an average of 15 to 20 pounds compared to 8 to 11 pounds with competitors. Foundayo's flexibility and effectiveness may provide Eli Lilly a competitive advantage in the weight loss medication market.
Read at www.businessinsider.com
Unable to calculate read time
Collection
[
|
...
]